Simcha Therapeutics is a clinical-stage immunobiology company pioneering the development of first-in-class engineered cytokine therapeutics with transformational promise for patients. The company is built on a foundation of scientific rigor to overcome biological challenges in clinically translatable pathways, exemplified by the first decoy-resistant interleukin-18 (IL-18). By unlocking the potential of IL-18, Simcha is developing its lead program (ST-067) as monotherapy and in combination with potentially several other anticancer agents. ST-067 is currently being studied in a Phase 1/2 clinical trial, in patients with solid tumors and who have progressed on other immunotherapeutic agents. Beyond IL-18, the company’s underlying approach to immune-biology and cytokine engineering has broader potential to support disease-modifying therapeutic options for a range of significant diseases.
Location: United States, Connecticut, New Haven
Employees: 11-50
Founded date: 2018
Investors 3
| Date | Name | Website |
| - | Connecticu... | ctinnovati... |
| - | Axial VC | axialvc.co... |
| 24.02.2022 | SR One | srone.com |
Mentions in press and media 4
| Date | Title | Description |
| 31.01.2022 | The metaverse could be ripe for crime, child abuse, and misinformation without regulation | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. If you’ve struggled to envision your virtual self in the metaverse, you’re not alone. Paid Conten... |
| 31.01.2022 | The metaverse could be ripe for crime, child abuse, and misinformation without regulation | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. If you’ve struggled to envision your virtual self in the metaverse, you’re not alone. Paid Conten... |
| 31.01.2022 | Simcha Therapeutics Raises $40M in Series B Funding | Simcha Therapeutics, a New Haven, Ct.-based biotechnology company developing cytokine-based cancer immunotherapies, raised $40m in Series B funding. The round was led by SR One Capital Management with participation from BVF Partners, Samsar... |
| 25.06.2020 | Simcha Therapeutics Launches With $25M | NEW HAVEN, CT, Simcha Therapeutics announces a $25 million Series A financing. >> Click here for more funding data on Simcha Therapeutics >> To export Simcha Therapeutics funding data to PDF and Excel, click here Simcha T... |